PPM1H

Across TCGA pan-cancer cohorts, PPM1H Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated PPM1H data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PPM1H Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPM1H expression acts as an unfavorable survival marker.

BLCA, SKCM, and BRCA are the cancer types where PPM1H Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.052	0.710	<.001	48	view →
SKCM	OS	Median	All	0.135	0.327	.012	14	view →
BRCA	OS	Median	II,III,IV	0.096	0.564	.020	12	view →
LUAD	OS	Median	III,IV	0.204	0.668	.002	12	view →
SCLC	OS	Median	All	0.082	0.653	.002	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
COAD	DFS	Median	II,III,IV	0.183	0.687	.008	6	view →
LIHC	DFS	Median	All	0.281	0.559	.010	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
GBM	OS	Median	All	0.070	0.416	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

PPM1H–BLCA (OS)

Open the BLCA breakdown →